Chemotherapy-Induced Anemia Market Analysis, Demand And Outlook 2025- 2034


Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics

What Is the Forecasted Market Size of the Chemotherapy-Induced Anemia Market by 2029?
The chemotherapy-induced anemia market size has grown strongly in recent years. It will grow from $2.62 billion in 2024 to $2.81 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increased prevalence of cancer and chemotherapy treatments, aging population leading to higher cancer incidence, expansion of chemotherapy drugs and regimens, improvement in overall cancer survival rates, awareness and diagnosis of anemia as a side effect.

The chemotherapy-induced anemia market size is expected to see strong growth in the next few years. It will grow to " $3.8 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to development of supportive care in oncology, rise in healthcare expenditure and infrastructure, personalized medicine and targeted cancer therapies, integration of biomarker-driven treatment approaches, increasing focus on early detection and intervention, integration of digital health technologies in patient management. Major trends in the forecast period include innovation of novel chemotherapy agents, integration of ml, advancements in cancer research and treatment protocols, integration of ai, collaboration between pharmaceutical companies and healthcare providers.

Get your free report sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12513&type=smp

What Are the Significant Market Forces Driving the Chemotherapy-Induced Anemia Market Performance?
The high prevalence of cancer and anemia is expected to propel the growth of the chemotherapy-induced anemia market going forward. Cancer is a disease where somebody's cells grow out of control and spread to other body regions. In cancer patients receiving aggressive chemotherapy, whether with or without radiation therapy, cancer and chemotherapy-induced anemia (CIA) are frequent occurrences. The medication stimulates the production of red blood cells in the bone marrow and can be used to treat chemotherapy-induced anemia. For instance, in 2023, according to Cancer Research UK, a UK-based independent cancer research organization, the incidence of head and neck cancer in the UK is projected to rise by 3% between 2023 and 2025, while deaths due to head and neck cancers are expected to increase by 12% between 2023 and 2025. Therefore, the high prevalence of cancer and anemia drives the growth of the chemotherapy-induced anemia market.

What Are the Primary Market Segments in the Chemotherapy-Induced Anemia Market?
The chemotherapy-induced anemiamarket covered in this report is segmented –

1) By Anemia: Mild Anemia; Moderate Anemia; Severe Anemia; Life-Threatening Anemia
2) By Treatment Type: RBC (Red Blood Cells) Transfusion; Erythropoiesis-Stimulating Agents (ESAs); Iron Supplementation
3) By End-User: Hospitals; Ambulatory Surgical Centers; Multispecialty Clinics; Cancer Research Centers; Cancer Rehabilitation Centers

Subsegments:
1) By Mild Anemia: Hemoglobin Levels 10-12 g/dL; Symptomatic Treatments
2) By Moderate Anemia: Hemoglobin Levels 8-10 g/dL; Erythropoiesis-stimulating Agents (ESAs); Blood Transfusion Management
3) By Severe Anemia: Hemoglobin Levels 6.5-8 g/dL; Intensive ESA Treatments; Frequent Blood Transfusions
4) By Life-Threatening Anemia: Hemoglobin Levels Below 6.5 g/dL; Emergency interventions; Critical Care And Monitoring

Which Major Trends Are Expected to Define the Chemotherapy-Induced Anemia Market Through 2029?
Major companies operating in the chemotherapy-induced anemia market are focused on developing innovative products such as biosimilars to enhance treatment efficacy and reduce costs. Biosimilars are biologic medical products that are highly similar to an already approved reference biologic drug, with no significant differences in safety, purity, or effectiveness. They are designed to offer more affordable alternatives to expensive biologic treatments while maintaining comparable therapeutic outcomes. For instance, in November 2022, Amneal Pharmaceuticals, Inc., a US-based pharmaceutical company, launched RELEUKO (filgrastim-ayow). This product references Neupogen® and is primarily indicated for the treatment of neutropenia, a conditio n often experienced by patients undergoing chemotherapy. offers significant benefits for patients undergoing cancer treatment. It is primarily indicated to decrease the incidence of infections associated with febrile neutropenia in patients receiving myelosuppressive chemotherapy, thereby enhancing their safety and recovery. Additionally, RELEUKO® aids in reducing the time to neutrophil recovery and the duration of fever following chemotherapy for acute myeloid leukemia, and it helps mitigate the complications of neutropenia in patients undergoing bone marrow transplantation.

Who Are the Established and Emerging Companies Competing in the Chemotherapy-Induced Anemia Market?
Major companies operating in the chemotherapy-induced anemia market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Hospira Inc., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., 3SBio Group, FibroGen Inc., Karger AG, Avesthagen Ltd., Blausen Medical Communications Inc., Aileron Therapeutics Inc.

Get the detailed chemotherapy-induced anemia market report today
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Which Region Is Expected to Dominate the Chemotherapy-Induced Anemia Market During the Forecast Period?
North America was the largest region in the chemotherapy-induced anemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Comments

Post a Comment

Popular posts from this blog

Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Scope, Share Analysis And Growth 2025

Image
Focused on real-world business use, this report highlights what’s changing in the hypertrophic cardiomyopathy (hcm) therapeutics market and what companies should prepare for next. What Is The Projected Market Size & Growth Rate Of The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market? The hypertrophic cardiomyopathy (hcm) therapeutics market size has grown marginally in recent years. It will grow from $1.34 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 1.5%. The growth in the historic period can be attributed to diagnostic advancements, increased disease awareness, drug development and approvals, rising healthcare expenditure, government initiatives and funding. The hypertrophic cardiomyopathy (hcm) therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.56 billion in 2029 at a compound annual growth rate (CAGR) of 3.4%. The growth in the forecast period can be attributed to genetic research and ...
Read more

Glycomics or Glycobiology Market Scope, Share Analysis And Growth 2025

Image
Backed by rigorous analysis and deep industry knowledge, this study is designed to support growth and investment decisions in the glycomics or glycobiology market. How Big Is The Glycomics or Glycobiology Market In 2025? The glycomics or glycobiology market size has grown rapidly in recent years. It will grow from $1.85 billion in 2024 to $2.13 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to increased awareness of glycans in biological systems, expansion of glycan-related database and resources, rise in collaborative research initiatives, advancements in glycan synthesis and engineering, glycan biomarker identification. The glycomics or glycobiology market size is expected to see rapid growth in the next few years. It will grow to $3.99 billion in 2029 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to glycan-focused artificial intelligence (AI) and data analy...
Read more

Smart Crop Monitoring Market Overview, Analysis And Demand By 2034

Image
Aimed at strategic decision-makers, this report explores current opportunities, emerging trends, and market dynamics shaping the smart crop monitoring sector. How Big Is The Smart Crop Monitoring Market In 2025? The smart crop monitoring market size has grown rapidly in recent years. It will grow from $3.47 billion in 2024 to $4.09 billion in 2025 at a compound annual growth rate (CAGR) of 18.0%. The growth in the historic period can be attributed to rising demand for high crop production, increasing global population, significant growth in IOT technology, rising need for sustainable agricultural practices, and increasing regulatory pressures. The smart crop monitoring market size is expected to see rapid growth in the next few years. It will grow to $7.83 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to the development of automated irrigation systems, the growing trend of farm-to-table movements, an increase in ag...
Read more